PBM
Income statement / Annual
Last year (2023), Psyence Biomedical Ltd. Common Shares's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Psyence Biomedical Ltd. Common Shares's net income was -$51.16 M.
See Psyence Biomedical Ltd. Common Shares’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$240.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$240.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
| Research and Development
Expenses |
$954,593.00
|
$1.61 M
|
$137,237.00
|
| General & Administrative
Expenses |
$1.72 M
|
$1.62 M
|
$1.70 M
|
| Selling & Marketing
Expenses |
$80,603.00
|
$7,029.00
|
$17,511.00
|
| Selling, General &
Administrative Expenses |
$1.80 M
|
$1.29 M
|
$334,288.00
|
| Other Expenses |
$879,344.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$2.75 M |
$1.29 M |
$334,288.00 |
| Cost And Expenses |
$2.75 M |
$1.29 M |
$334,288.00 |
| Interest Income |
$2,134.00 |
$1,554.00 |
$0.00 |
| Interest Expense |
$52,941.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$240.00
|
$0.00
|
$0.00
|
| EBITDA |
-$2.75 M
|
-$1.29 M
|
-$334,290.00
|
| EBITDA Ratio |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$48.41 M
|
$9.31 M
|
$8.56 M
|
| Income Before Tax |
-$51.16 M |
$8.01 M |
$8.23 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
-$51.16 M |
$8.01 M |
$8.23 M |
| Net Income Ratio |
0 |
0 |
0 |
| EPS |
-7.85 |
-0.64 |
0 |
| EPS Diluted |
-7.85 |
-0.64 |
0 |
| Weighted Average Shares
Out |
$6.52 M
|
$5.00 M
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$6.52 M
|
$5.00 M
|
$0.00
|
| Link |
|
|
|
